Pigment, tone & photoprotection
One of 5 mechanistic pathways to ✨ Skin, hair & aesthetics · 13 options
UV is responsible for the large majority of visible facial ageing. Nothing in this pathway replaces sunscreen — they raise the threshold at which damage happens and address pigment that already exists.
Melasma is frequently hormonal, and thyroid disease causes pigment change directly. Worth ruling out before spending months on topicals.
TSH (Thyroid-Stimulating Hormone)Vitamin D (25-Hydroxy)FerritinComprehensive Metabolic Panel (CMP)🥬 Full Micronutrient Screen covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Melanotan 1
Afamelanotide — an MC1R agonist that increases eumelanin, and it is actually approved for erythropoietic protoporphyria. Photoprotection through your own pigment. The melanoma-surveillance concern is that it darkens existing naevi and can mask change.
💉 Melanotan 2
Non-selective melanocortin agonism — tanning plus libido plus nausea plus mole darkening. Less targeted than MT-1 in every direction.
💉 Glutathione
Inhibits tyrosinase and shifts melanin synthesis from eumelanin toward pheomelanin, which is the basis of the skin-lightening use across Asia. IV use for cosmetic lightening has documented safety incidents and is not an approved indication.
💉 Decapeptide-12
A tyrosinase inhibitor with topical trial data for melasma — targeted at pigment production rather than bleaching existing pigment.
💉 Tretinoin
Accelerates turnover of pigmented keratinocytes; standard in melasma protocols.
🧬 Polypodium Leucotomos
Oral fern extract that raises the minimal erythema dose measurably in controlled human studies — real systemic photoprotection, and useful where sunscreen cannot reach or be reapplied.
🧬 Astaxanthin
Trials show reduced UV-induced skin damage and improved elasticity. Also crosses into skin lipid membranes effectively.
🧬 Niacinamide
Oral nicotinamide reduced new non-melanoma skin cancers by 23% in the ONTRAC randomized trial — one of the most concrete results on this page. Topically it also reduces pigment transfer to keratinocytes.
🧬 Lutein & Zeaxanthin
Accumulates in skin as well as retina, with trials showing improved skin hydration and photoprotection.
🧬 Vitamin C
Regenerates vitamin E and limits UV-induced oxidative damage, on top of the collagen role.
🧬 Vitamin E
Lipid-phase protection in the cell membrane; synergistic with C, which recycles it.
🧬 Grape Seed Extract
Proanthocyanidins with trial data for melasma improvement.
🧬 Pycnogenol
Improved melasma area and skin hydration in trials, plus a photoprotective effect.
What actually decides this outcome, in order of size
Two different jobs share this page: raising the threshold at which damage happens, and removing pigment that already exists. Ranked by how much of the outcome each one owns:
- Ultraviolet exposure itself, which nothing here replaces. Sunscreen, shade and clothing are the intervention; every oral item below raises a threshold rather than removing a dose. That is not a disclaimer, it is the ranking, and the systemic agents earn their place precisely where sunscreen cannot reach or cannot be reapplied.
- What the endpoint is, because this page has both a real one and a convenient one. The convenient one is minimal erythema dose, which an oral supplement can shift measurably: an extract raised it in controlled human studies Gonzalez 1997 Middelkamp-Hup 2004 and a modern product has been assessed for enhancing sun protection Hussain 2025. The real one is lesion count over years, and only one molecule here has ever been tested against it.
- The full arc of that one molecule, which is the most instructive story in the skin estate. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention reported a reduction in new non-melanoma skin cancers Chen 2015. A subsequent trial in transplant recipients addressed a different population Allen 2023. A systematic review and meta-analysis pooled the field Tosti 2023, and a 2026 review is titled around the jury still being out Tan 2026. One positive trial is where a claim starts, not where it ends.
- Whether you are treating pigment production or pigment transfer, because they are different targets. A tyrosinase-inhibiting oligopeptide has topical trial data in melasma Hantash 2012, and the standard combination cream works on turnover and synthesis together Hu 2025. Nothing oral bleaches existing pigment usefully.
- Whether the product changes your own melanin, because that carries a surveillance problem. Afamelanotide is an approved melanocortin-1 receptor agonist with long-term observational data in erythropoietic protoporphyria Biolcati 2015 and full prescribing information U.S. Food and Drug Administration 2019. The unlicensed relative is a different risk: melanotan II nasal spray has been discussed as a possible risk factor for oral mucosal melanoma Yassin Alsabbagh 2025, and darkening existing naevi masks the change dermatologists watch for.
- Whether the lightening route is safe, which for one popular product it is not as sold. Glutathione as a skin-lightening agent and in melasma has been reviewed systematically Sarkar 2024. Intravenous use for cosmetic lightening is not an approved indication and has documented safety incidents.
The order to run these in, and what has to be true first
Block the exposure, then raise the threshold, then treat existing pigment, and treat pigment last because it recurs without the first step. The ordering principle is that everything below is a modifier on a dose.
- Sunscreen, shade and clothing, before any purchase on this page. The oral agents shift a threshold by a factor that is meaningful in a laboratory and small against a day outdoors Gonzalez 1997. Using one instead of the other is the failure this whole pathway exists to prevent.
- Niacinamide next, because it is the only item here with a hard clinical endpoint behind it, and read the whole file. The phase 3 result Chen 2015, the transplant population Allen 2023, the pooled analysis Tosti 2023 and the 2026 reassessment Tan 2026. It is cheap, it is well tolerated, and the case for it is a case about a specific high-risk population rather than about everybody.
- Polypodium Leucotomos next if the exposure is unavoidable and reapplication is not possible. The minimal erythema dose work is real and repeated Gonzalez 1997 Middelkamp-Hup 2004, and a modern assessment of a combined product exists Hussain 2025. It is a systemic top-up, not a replacement.
- Astaxanthin and the carotenoids next, on oxidative rather than absorptive grounds. The meta-analysis is on oxidative stress and inflammation biomarkers Ma 2022, and bioactivity depends on stereoisomer composition and extraction method Snell 2022, so the source is part of the dose.
- Vitamin C and Vitamin E together rather than separately, because one regenerates the other. This is the cheapest pairing on the page and the one with the least dramatic claim.
- Topicals for existing pigment, and expect months. Decapeptide-12 inhibits tyrosinase with melasma trial data Hantash 2012; Tretinoin accelerates turnover of pigmented keratinocytes and is standard in combination protocols Hu 2025; Pycnogenol and Grape Seed Extract have melasma data of their own.
- Melanotan 1 is a licensed drug for a rare photodermatosis, not a tanning product. It has prescribing information U.S. Food and Drug Administration 2019 and long-term observational data in its licensed indication Biolcati 2015. Melanotan 2 is the unlicensed, non-selective relative with a published melanoma concern attached to a nasal route Yassin Alsabbagh 2025.
- Glutathione by injection for lightening is the item to decline. The systematic review is the place to read why Sarkar 2024: it is an unapproved indication with documented safety incidents, and the mechanism it relies on shifts melanin synthesis rather than protecting anything.
What gets bought for this that cannot move it
The category that fails structurally is the oral supplement bought as a sunscreen substitute. Raising a minimal erythema dose is a measured effect Middelkamp-Hup 2004, and the number it multiplies is small next to the difference between wearing sunscreen and not. The product does what it says and the reader does the arithmetic wrong, which is a failure of framing rather than of chemistry.
The surrogate here is erythema, and it is measuring the wrong damage. Redness is an acute inflammatory response; the outcomes that matter are mutation burden and lesion count over decades. Only one molecule on this page has ever been tested against the second kind of endpoint Chen 2015, and its subsequent history is exactly the reason surrogates are dangerous: a positive phase 3, a different result in a different population Allen 2023, a pooled analysis Tosti 2023, and a 2026 review that declines to close the question Tan 2026. Anything on this page still sitting on an erythema endpoint has not begun that journey.
The specific harm to name is melanoma surveillance. A melanocortin agonist darkens existing naevi. The licensed one is used under specialist supervision with a defined indication U.S. Food and Drug Administration 2019 Biolcati 2015; the unlicensed one is bought online, is often taken by a nasal route, and has a published discussion of oral mucosal melanoma risk attached to that route Yassin Alsabbagh 2025. Losing the ability to notice a changing mole is a real cost even if the product itself were inert.
If the goal underneath is different, so is the page. If the concern is lines and laxity rather than pigment, Collagen synthesis & dermal matrix and Expression lines & topical neuromodulation. If melasma is worsening in pregnancy or on a combined oral contraceptive, that is hormonal and belongs with Female hormonal balance. A new, changing, asymmetric or bleeding pigmented lesion is a dermatology appointment today rather than a supplement decision. And rigorous sun avoidance lowers cutaneous vitamin D synthesis, which is a real trade and is on the read-out below rather than in a footnote.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Nothing here changes visible pigment before twelve weeks, because epidermal turnover plus melanosome clearance sets the floor; and sustained rigorous photoprotection lowers Vitamin D (25-Hydroxy) measurably, which is the one blood change this pathway reliably produces and almost nobody looks for.
- Vitamin D (25-Hydroxy) at baseline and 6 months. Six months because the seasonal swing is larger than the intervention, so a matched interval is what makes the comparison mean anything. This is the cost side of doing photoprotection properly and it is correctable.
- Standardized photographs, same lighting, same distance, no makeup, monthly for six months. This is the endpoint the melasma trials used Hantash 2012 Hu 2025, and it is the only instrument that survives a change in bathroom lighting.
- TSH (Thyroid-Stimulating Hormone) with Thyroid Antibodies (TPO + TgAb) once if melasma is the presentation. Thyroid autoimmunity travels with melasma often enough to be worth one draw, and it changes nothing about the topical plan while changing what else gets investigated.
- Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC) with Differential at baseline if any intravenous product is being considered, which it should not be. The systematic review of glutathione for lightening is the document to read first Sarkar 2024; the bloods exist because an unapproved intravenous cosmetic route has documented incidents.
- A full-body skin check with a clinician annually, and photographs of any changing lesion. This is the endpoint that matters on the chemoprevention half of the page Chen 2015, and it is the one thing a melanocortin agonist actively interferes with Yassin Alsabbagh 2025.
What will fool you. Pigment fades in winter and returns in summer, so a topical started in October will look like it worked. Photographs taken under different lighting differ more than three months of treatment does. A minimal erythema dose shifted in a laboratory does not translate linearly to a day outdoors Gonzalez 1997. Astaxanthin products differ in stereoisomer composition and extraction, so equal milligram doses are not equal exposures Snell 2022. And one positive chemoprevention trial in one population is where the question opened rather than where it closed Tan 2026.
Sources read for these sections
- Chen AC, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.. New England Journal of Medicine 2015 · PMID 26488693
- Allen NC, et al. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.. New England Journal of Medicine 2023 · PMID 36856616
- Tosti G. The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis. Nutrients 2023 · PMID 38201930
- Tan E. Nicotinamide for Skin Cancer Chemoprevention: The Jury Was Out and Still is. American Journal of Clinical Dermatology 2026 · PMID 41505062
- Gonzalez S, et al. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatology, Photoimmunology and Photomedicine, 1997 · PMID 9361129
- Middelkamp-Hup MA, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. Journal of the American Academy of Dermatology, 2004 · PMID 15583582
- Hussain A, Thakker S, Galaria N. Effectiveness of an oral supplement containing Polypodium leucotomos in enhancing sun protection: a clinical evaluation of minimal erythema dose pre- and post-consumption. Archives of Dermatological Research, 2025 · PMID 40095119
- Ma B. Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials. Nutr Res 2022 · PMID 35091276
- Snell TW. Astaxanthin Bioactivity Is Determined by Stereoisomer Composition and Extraction Method. Nutrients 2022 · PMID 35406135
- Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.. Br J Dermatol 2015 · PMID 25494545
- U.S. Food and Drug Administration. SCENESSE (afamelanotide) implant, for subcutaneous use - full prescribing information (NDA 210797).. FDA approved labeling, revision 2019
- Yassin Alsabbagh A, et al. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. International Journal of Oral and Maxillofacial Surgery 2025 · PMID 40210573
- Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. International Journal of Dermatology 2024 · PMID 39444151
- Hantash BM, et al. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. Journal of Drugs in Dermatology 2012 · PMID 22527440
- Hu H, et al. Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI-LUMA for the Treatment of Moderate-To-Severe Melasma in Chinese Patients: A Randomized, Single-Center, Placebo-Controlled Trial. Journal of Cosmetic Dermatology 2025 · PMID 40296512
The other 4 routes to skin, hair & aesthetics
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Skin, hair & aesthetics Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Skin, hair & aesthetics Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
UV is responsible for the large majority of visible facial ageing. Nothing in this pathway replaces sunscreen — they raise the threshold at which damage happens and address pigment that already exists.
13 options are mapped to this pathway in the Vault, including Melanotan 1, Melanotan 2, Glutathione, Decapeptide-12. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 11 carry clinical validation and 2 are mechanistic predictions.
Melasma is frequently hormonal, and thyroid disease causes pigment change directly. Worth ruling out before spending months on topicals. The markers worth checking are TSH (Thyroid-Stimulating Hormone), Vitamin D (25-Hydroxy), Ferritin, Comprehensive Metabolic Panel (CMP).
Unproven is not the same as ineffective. Of the 13 options on this pathway, 11 have clinical validation and 2 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Pigment, tone & photoprotection. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.